Palmitoylethanolamide: the research, in one place
Palmitoylethanolamide (PEA) is a fatty acid amide that the body makes. Researchers have studied it since the 1950s, in people and in animals, by mouth and on the skin. This site lists that research, with each study's design, size, dose and limits. It does not give advice and does not sell anything.
601 studies from 2001 to 2026, including 69 randomised controlled trials. Each entry was checked against its source.
By species
- Humans 349 studies
- Dogs 20 studies
- Cats 11 studies
- Horses 2 studies
- Other animals and laboratory 332 studies
By route and product
Human research by topic
- Chronic and neuropathic pain 112 studies
- Joints 12 studies
- Pelvic pain and endometriosis 19 studies
- Migraine and headache 10 studies
- Sleep 8 studies
- Gut 24 studies
- Mood and brain 91 studies
- Respiratory and immune 24 studies
- Sense of smell 14 studies
- Eyes 11 studies
- Metabolic health 24 studies
- Exercise recovery 10 studies
- Safety in human trials 19 studies
Background
Recently added
- Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults
This open-label study found:
Open-label, no control groupHumans - Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma
The abstract reports no palmitoylethanolamide-specific findings or numbers.
ReviewHumansOther animals - Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors
PEA increased the time to seizure onset and shortened seizure duration after PTZ injection.
Laboratory studyOther animals - Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis
PEA and related lipids were higher in atopic skin than in healthy skin, PEA most of all.
Laboratory studyDogs
Browse the full database · Research log and RSS feed · How to read a study page